US For 1st Time Sees A Drop In Obesity Rates

US obesity rates drop for the first time in a decade likely due to popular weight loss medications
The secret agent in the decrease might be semaglutide, a GLP-1 receptor agonist that fuels popular weight loss drugs like Ozempic and Wegovy, according to the study authors.
Obesity Rates in the U.S. Drop for the First Time in a Decade, ‘Proliferation’ of Ozempic May Be a Reason
The study followed nearly 17 million people, the majority of whom were in the 26-75 age range, and found that after climbing steadily since 2013, rates of obesity in the U.S. fell 0.15% in 2023, according to a research letter published in the Journal of the American Medical Association (JAMA) on Dec. 13.
US obesity rates drop for 1st time in a decade, with possible help from weight loss medications
Brownstein and his team noted that women and adults aged 66 to 75 saw the largest decreases in obesity. People living in the South, where they had the highest dispensing rate of weight loss drugs known as GLP-1 receptor agonists, also saw a meaningful decline in obesity.
Obesity prevalence and BMI decrease in the US for the first time in a decade
Obesity prevalence in the US decreased in 2023, with significant drops in the South, highlighting the impact of GLP-1RA medications on health trends.
U.S. obesity rates decline for first time in more than a decade
U.S. obesity rates have decreased for the first time in more than a decade, with new weight loss medications potentially playing a role in the turnaround.
US obesity rate declines for the first time in a decade, weight-loss drugs play key role
Obesity rates in the US dropped slightly in 2023 for the first time in over a decade, with rates falling from 46% to 45.6%. A key driver of this trend is the increased use of semaglutide, the active ingredient in weight loss drugs like Ozempic and Wegovy.
US For The First Time Sees A Drop In Obesity Rates
A new study reveals a slight drop in U.S. obesity rates, driven by weight loss drugs, lifestyle changes post-COVID, and regional trends. Experts caution that long-term impacts remain uncertain despite this encouraging sign.
New study finds first US obesity decline in 10 years. Is Ozempic a leading factor?
Results of the study indicate that Black women in the U.S., ages 66-75, saw the largest decrease in obesity between 2022-2023 ...
FDA says knockoff versions of Lilly obesity drug must come off the market
Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...
A Rift in Trump World Over How to Make America Healthier
Statements by Robert F. Kennedy Jr. and Elon Musk tap into a dispute over whether lifestyle changes or drugs are a better way ...
The American Journal of Managed Care2d
Top 5 Most-Read Obesity Articles in 2024
The most-read obesity articles of 2024 mostly focused on insurance coverage of weight loss medications and costs.
Semaglutide: a game-changer in the fight against obesity
Semaglutide and similar medications could be key players in bending the curve but enduring change ultimately hinges on a ...